Cite

HARVARD Citation

    Virani, S. et al. (2019). Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. Circulation. 139 (3), p. . [Online]. 
  
Back to record